John Hamill - SrVP/CFO/Prin Fin & Acct Ofcr at Aprea Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
SrVP/CFO/Prin Fin & Acct Ofcr
Issuer Symbol
APRE on Nasdaq
All Insider Reports
All Insider Reports

John Hamill - trading volume in the past year for Aprea Therapeutics, Inc.

Holdings reported by John Hamill for Aprea Therapeutics, Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Common Stock 33,433 $29,755 $0.8900 30 Jan 2026 Direct
Stock Options (Right to Buy) 13,460 27 Mar 2025 Direct Common Stock
Common Warrant 5,700 30 Jan 2026 Direct Common Stock

Transactions reported by John Hamill for Aprea Therapeutics, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.